Eflepedocokin alfa is a recombinant IL-22-Fc fusion protein manufactured in Chinese hamster ovary cells that is composed of 2 human interleukin 22 (IL-22) molecules linked to an immunoglobulin constant region... It is being developed by Evive Biotech (previously known as Generon BioMed Inc).
- Mechanism
- Curator reviewed · 2 references
F-652 incorporates human interleukin 22’s (IL-22) natural epithelial cell growth-promoting activity as IL-22 plays critical roles in promoting tissue repair and suppressing bacterial infection. F-652 is currently being investigated against acute graft vs host disease, acute alcoholic hepatitis, inflammatory diseases, organ injuries, eventual fatal organ failures, and COVID-19.
- Also known as
- F-652 (RECOMBINANT FUSION PROTEIN CONSISTING OF TWO HUMAN INTERLEUKIN-22 (IL-22) MOLECULES LINKED TO AN IMMUNOGLOBULIN CONSTANT REGION (IGG2-FC)) · IL-22 DIMER F-652 · IL-22 fusion protein · RECOMBINANT HUMAN INTERLEUKIN-22 IGG2-FC
- Code names
- F-652
Resolves to
What you can answer from here — as of July 08, 2026
Which drugs share a target with Eflepedocokin alfa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account